ChemGenex Pharmaceuticals Limited (ASX: CXS, Nasdaq: CXSP), based in Melbourne, Australia and Menlo Park, California, U.S.A., and Stragen Pharma S.A., based in Geneva, Switzerland, today announced an international alliance to accelerate the clinical development of ChemGenex's lead anti-cancer therapeutic, CeflatoninĀ®. CeflatoninĀ® is currently in a Phase 2 Clinical Trial at the M.D. Anderson Cancer Center in Houston, Texas treating chronic myeloid leukemia (CML) patients who are resistant to GleevecĀ®.
 
[CML]
A group of CMLHope.Com
Subscribe: [EMAIL PROTECTED]
Web Site: http://groups.cmlhope.com 

Reply via email to